Cline Christopher R. 4
4 · Travere Therapeutics, Inc. · Filed Dec 3, 2025
Insider Transaction Report
Form 4
Cline Christopher R.
CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2025-12-01$16.23/sh+20,000$324,600→ 112,083 total - Sale
Common Stock
2025-12-01$35.01/sh−20,000$700,202→ 92,083 total - Exercise/Conversion
Employee stock option (right to buy)
2025-12-01−20,000→ 0 totalExercise: $16.23Exp: 2026-05-19→ Common Stock (20,000 underlying)
Footnotes (3)
- [F1]This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016, with an expiration date of May 19, 2026.
- [F2]The weighted average sale price for the transaction reported was $35.0101, and the range of prices were between $34.64 and $35.41. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
- [F3]The stock option is fully vested and exercisable.